Literature DB >> 30801677

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.

Jacob T Brown1, Jeffrey R Bishop2, Katrin Sangkuhl3, Erika L Nurmi4, Daniel J Mueller5,6, Jean C Dinh7, Andrea Gaedigk7,8, Teri E Klein3, Kelly E Caudle9, James T McCracken4, Jose de Leon10, J Steven Leeder7,8.   

Abstract

Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30801677      PMCID： PMC6612570          DOI： 10.1002/cpt.1409

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  34 in total

1.  Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

Authors:  Christopher J Kratochvil; Jeffrey H Newcorn; L Eugene Arnold; David Duesenberg; Graham J Emslie; Humberto Quintana; Elias H Sarkis; Karen Dineen Wagner; Haitao Gao; David Michelson; Joseph Biederman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-09       Impact factor: 8.829

2.  The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Authors:  A Gaedigk; S D Simon; R E Pearce; L D Bradford; M J Kennedy; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

3.  Enhancement of atomoxetine serum levels by co-administration of paroxetine.

Authors:  Michael Paulzen; Hans-Willi Clement; Gerhard Gründer
Journal:  Int J Neuropsychopharmacol       Date:  2007-09-28       Impact factor: 5.176

4.  Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.

Authors:  John-Michael Sauer; G Douglas Ponsler; Edward L Mattiuz; Amanda J Long; Jennifer W Witcher; Holly R Thomasson; Karl A Desante
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

5.  CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.

Authors:  David Michelson; Holly A Read; Dustin D Ruff; Jennifer Witcher; Shuyu Zhang; James McCracken
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2007-02       Impact factor: 8.829

6.  Identification of the human cytochromes P450 responsible for atomoxetine metabolism.

Authors:  Barbara J Ring; Jennifer S Gillespie; James A Eckstein; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2002-03       Impact factor: 3.922

7.  A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).

Authors:  Nicolas Ramoz; Claudette Boni; Anncatherine M Downing; Sandra L Close; Sandra L Peters; Angela M Prokop; Albert J Allen; Michel Hamon; Diane Purper-Ouakil; Philip Gorwood
Journal:  Neuropsychopharmacology       Date:  2009-04-22       Impact factor: 7.853

8.  Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study.

Authors:  Jeffrey H Newcorn; Virginia K Sutton; Margaret D Weiss; Calvin R Sumner
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-05       Impact factor: 8.829

9.  Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele.

Authors:  Yi M Cui; Choo H Teng; Alan X Pan; Eunice Yuen; Kwee P Yeo; Ying Zhou; Xia Zhao; Amanda J Long; Mark E Bangs; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2007-07-04       Impact factor: 4.335

10.  CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.

Authors:  Paula T Trzepacz; David W Williams; Peter D Feldman; Rebecca E Wrishko; Jennifer W Witcher; Jan K Buitelaar
Journal:  Eur Neuropsychopharmacol       Date:  2007-08-14       Impact factor: 4.600
View more
  42 in total

Review 1.  Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.

Authors:  Nada A Elsayed; Kaila M Yamamoto; Tanya E Froehlich
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

Review 2.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

3.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.

Authors:  Abdullah Al Maruf; Mikayla Fan; Paul D Arnold; Daniel J Müller; Katherine J Aitchison; Chad A Bousman
Journal:  Can J Psychiatry       Date:  2020-02-17       Impact factor: 4.356

5.  Ontogeny of Pediatric Pharmacogenetics: Celebrating the Past and Vision for the Future.

Authors:  J Steven Leeder
Journal:  J Pediatr Pharmacol Ther       Date:  2021-12-22

Review 6.  Keeping pace with CYP2D6 haplotype discovery: innovative methods to assign function.

Authors:  Karen E Brown; Jack W Staples; Erica L Woodahl
Journal:  Pharmacogenomics       Date:  2022-01-27       Impact factor: 2.533

Review 7.  A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD).

Authors:  Samuele Cortese; Jeffrey H Newcorn; David Coghill
Journal:  CNS Drugs       Date:  2021-08-17       Impact factor: 5.749

Review 8.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

9.  Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.

Authors:  Ina Liko; Yee Ming Lee; Danielle L Stutzman; Allison B Blackmer; Kimberly M Deininger; Ann M Reynolds; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2021-03-04       Impact factor: 2.533

Review 10.  Pharmacogenetic factors affecting β-blocker metabolism and response.

Authors:  Cameron D Thomas; Julie A Johnson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-09-09       Impact factor: 4.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.